Efficacy Of Theconcomitant Quadruple Therapy for The Eradication Of Helicobacter Pylori

Aims Helicobacter pylori (H. pylori) infection is widespread throughout the world, with a prevalence ranging from 30 to 80 %. The bacteria is resistant to gastric acidity due to its bacteriological characteristics. It is implicated in the occurrence of many potentially serious peptic diseases. Its eradication is a real therapeutic challenge.

The aim of our study was to evaluate the efficacy of concomitant quadruple therapy in the eradication of H. pylori in a Tunisian center.

Methods We conducted a descriptive retrospective study from 2018 to 2020. We included all patients who received first-line treatment for the eradication of H. pylori. The protocol used was concomitant quadruple therapy (proton pump inhibitor (PPI) + Amoxicillin + Metronidazole + Clarithromycin for 14 days). The patients had previously a proof of H. pylori infection by gastroscopy with histology.

Results We included 66patients. The mean age was 48years (17years-80years). The Sex Ratio M/F was0.6. The mean body mass index(BMI) was28.2, 12.1 %of patients were smokers.

The diagnosis of H. pylori infection was made by gastroscopy + histology in all patients. All patients received a first line treatment with concomitant quadruple therapy.

Our patients adherence to treatment was100 %. The tolerance to treatment was in71 % of cases. The most frequently noted adverse effects were: dysgeusia in31.8 %, dizziness in18.2 % of cases, headache in9 % of cases and nausea with abdominal pain in9 % of cases. No cases of interruption of treatment were observed.

Eradication of HP was observed in 72.1 % of cases. We used quadruple bismuth therapy as a second line in 6.2 % of cases.

We did not find any correlation between treatment failure and the age, gender, and BMI.

Conclusions The success rate of the concomitant quadruple therapy for the eradication of H. pylori was 72.1 % and this is probably due to the increasing resistance of H. Pylori to clarithromycin.

Citation: Harbi R, Mrabet S, Zaouga S et al. eP68 EFFICACY OF THECONCOMITANT QUADRUPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI. Endoscopy 2021; 53: S118.

Publication History

Article published online:
19 March 2021